Business Wire

AFWERX, the Innovation Arm of the U.S. Air Force, Awards Phase II STTR Contract to Transcend Air

21.6.2022 14:03:00 EEST | Business Wire | Press release

Share

Transcend Air announced today that it was awarded a Phase II Small Business Technology Transfer research and development contract from AFWERX, a Technology Directorate of the Air Force Research Laboratory. Transcend Air, in partnership with Auburn University, will further develop advanced flight control laws for high-speed flight with its Vy 400 vertical takeoff and landing aircraft (VTOL). “Specifically, the high speed flight is referred to as nap-of-the-earth (NOE) flight, which is a demanding regime where an aircraft stays low and follows the contours of terrain to remain undetected,” commented Peter Schmidt, COO of Transcend Air and Principal Investigator.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005201/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Advanced flight control laws developed in simulation (Photo: Business Wire)

Transcend Air is extending its work with Professor Imon Chakraborty and his Vehicle Systems, Dynamics, and Design Laboratory (VSDDL.com) and newly teaming with Professor Ehsan Taheri and his Aero-Astro Computational and Experimental Lab (ACE Lab). Control software will be demonstrated that enables the Vy 400 aircraft to automatically fly nap-of-the-earth in both simulation and real-world flight with 1/5th scale aircraft. The software reduces pilot workload and enables sustained flight in very close proximity to terrain at speeds two to three times faster than helicopters. This capability facilitates the mission of rescuing downed aircrews in one-quarter to one-eighth of the time it currently takes. With that improvement it is projected that nearly double the number of people can be rescued as before.

AFWERX is an arm of the United States Air Force that supports aircraft technology development for commercial and military purposes. VSDDL and ACE Lab are part of the Department of Aerospace Engineering at Auburn University in Auburn, Alabama.

ABOUT TRANSCEND AIR CORPORATION

Transcend Air has designed a family of high speed tiltwing VTOL aircraft. Its Vy 400 is three times faster than helicopters with half the operating costs. Expectations are that the Vy 400 will dominate the VIP transport helicopter segment. It will also enable a new city-center to city-center Aerial Regional Transport service that is up to five times faster door to door, and lower cost as compared with current air travel options. Since 2009, Transcend Air has built and flown 15 prototype VTOL aircraft, giving their patented Vy a long lineage of real-world experience. The Vy 400 will not require new regulatory regimes or air traffic control systems because it utilizes proven technologies that include the General Electric CT7-8 engine and BRS Aerospace whole-aircraft parachute. The Vy 400 brings with it the promise of civil VTOL flight that is within everyone’s reach.

For additional information see www.Transcend.aero

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Peter Schmidt, peter@transcend.aero
t. 781-883-4818

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye